Literature DB >> 19647847

Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.

Mars Stone1, Zhong-Min Ma, Meritxell Genescà, Linda Fritts, Shelley Blozois, Michael B McChesney, Christopher J Miller.   

Abstract

In non-human primate models of AIDS, attenuated lentiviruses provide the most reliable protection from challenge with pathogenic virus but the extent to which the vaccine virus replicates after challenge is unclear. At 7 and 14 days after vaginal challenge with pathogenic SIVmac239, plasma SIVenv RNA levels were significantly lower in female macaques immunized 6 months earlier with live, attenuated SHIV89.6 compared to unimmunized control animals. In 2 SHIV-immunized, unprotected macaques SIV replication produced moderate-level plasma viremia with dissemination of challenge virus to all tissues on day 14 after challenge. In protected, SHIV-immunized monkeys, SIV replication was controlled in all tissues, from the day of challenge through 14 days post-challenge. Further, in CD8(+) T cell-depleted SHIV-immunized animals, SIV replication and dissemination were more rapid than in control animals. These findings suggest that replication of a pathogenic AIDS virus can be controlled at the site of mucosal inoculation by live-attenuated lentivirus immunization.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19647847      PMCID: PMC2754392          DOI: 10.1016/j.virol.2009.06.052

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Protection against late-onset AIDS in macaques prophylactically immunized with a live simian HIV vaccine was dependent on persistence of the vaccine virus.

Authors:  Glenn A Mackay; Zhenqian Liu; Dinesh K Singh; Marilyn S Smith; Sampa Mukherjee; Darlene Sheffer; Fenglan Jia; Istvan Adany; Kelvin H Sun; Sukhbir Dhillon; Wu Zhuge; Opendra Narayan
Journal:  J Immunol       Date:  2004-09-15       Impact factor: 5.422

2.  Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.

Authors:  R Shibata; C Siemon; S C Czajak; R C Desrosiers; M A Martin
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Mechanisms of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection.

Authors:  R Stebbings; J Stott; N Almond; R Hull; J Lines; P Silvera; R Sangster; T Corcoran; J Rose; S Cobbold; F Gotch; A McMichael; B Walker
Journal:  AIDS Res Hum Retroviruses       Date:  1998-09-01       Impact factor: 2.205

4.  Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239.

Authors:  C J Miller; M B McChesney; X Lü; P J Dailey; C Chutkowski; D Lu; P Brosio; B Roberts; Y Lu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

5.  Immunophenotypic characterization of simian immunodeficiency virus-infected dendritic cells in cervix, vagina, and draining lymph nodes of rhesus monkeys.

Authors:  J Hu; M Pope; C Brown; U O'Doherty; C J Miller
Journal:  Lab Invest       Date:  1998-04       Impact factor: 5.662

6.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

7.  A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge.

Authors:  B L Lohman; M B McChesney; C J Miller; E McGowan; S M Joye; K K Van Rompay; E Reay; L Antipa; N C Pedersen; M L Marthas
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

8.  Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251.

Authors:  L Wakrim; R Le Grand; B Vaslin; A Chéret; F Matheux; F Theodoro; P Roques; I Nicol-Jourdain; D Dormont
Journal:  Virology       Date:  1996-07-15       Impact factor: 3.616

9.  Depo-Provera abrogates attenuated lentivirus-induced protection in male rhesus macaques challenged intravenously with pathogenic SIVmac239.

Authors:  Meritxell Genescà; Jun Li; Linda Fritts; Paul Chohan; Kristen Bost; Tracy Rourke; Shelley A Blozis; Michael B McChesney; Christopher J Miller
Journal:  J Med Primatol       Date:  2007-08       Impact factor: 0.667

10.  The development of PCR based assays for the detection and differentiation of simian immunodeficiency virus in vivo.

Authors:  J Rose; P Silvera; B Flanagan; P Kitchin; N Almond
Journal:  J Virol Methods       Date:  1995-02       Impact factor: 2.014

View more
  16 in total

1.  Antiviral antibodies and T cells are present in the foreskin of simian immunodeficiency virus-infected rhesus macaques.

Authors:  Kristina Rothaeusler; Zhong-Min Ma; Huma Qureshi; Timothy D Carroll; Tracy Rourke; Michael B McChesney; Christopher J Miller
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Increased inherent intestinal granzyme B expression may be associated with SIV pathogenesis in Asian non-human primates.

Authors:  A T Hutchison; J E Schmitz; C J Miller; K J Sastry; P N Nehete; A M Major; A A Ansari; N Tatevian; D E Lewis
Journal:  J Med Primatol       Date:  2011-07-07       Impact factor: 0.667

3.  Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

Authors:  Gregory Q Del Prete; Matthew Scarlotta; Laura Newman; Carolyn Reid; Laura M Parodi; James D Roser; Kelli Oswald; Preston A Marx; Christopher J Miller; Ronald C Desrosiers; Dan H Barouch; Ranajit Pal; Michael Piatak; Elena Chertova; Luis D Giavedoni; David H O'Connor; Jeffrey D Lifson; Brandon F Keele
Journal:  J Virol       Date:  2013-02-13       Impact factor: 5.103

Review 4.  New directions for HIV vaccine development from animal models.

Authors:  Michael B McChesney; Christopher J Miller
Journal:  Curr Opin HIV AIDS       Date:  2013-09       Impact factor: 4.283

5.  Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Authors:  Huma Qureshi; Zhong-Min Ma; Ying Huang; Gregory Hodge; Michael A Thomas; Janet DiPasquale; Veronique DeSilva; Linda Fritts; Andrew J Bett; Danilo R Casimiro; John W Shiver; Marjorie Robert-Guroff; Michael N Robertson; Michael B McChesney; Peter B Gilbert; Christopher J Miller
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 6.  Preventing mucosal HIV transmission with topical microbicides: challenges and opportunities.

Authors:  Florian Hladik; Gustavo F Doncel
Journal:  Antiviral Res       Date:  2010-12       Impact factor: 5.970

7.  Extralymphoid CD8+ T cells resident in tissue from simian immunodeficiency virus SIVmac239{Delta}nef-vaccinated macaques suppress SIVmac239 replication ex vivo.

Authors:  Justin M Greene; Jennifer J Lhost; Benjamin J Burwitz; Melisa L Budde; Caitlin E Macnair; Madelyn K Weiker; Emma Gostick; Thomas C Friedrich; Karl W Broman; David A Price; Shelby L O'Connor; David H O'Connor
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

8.  Depo-provera treatment does not abrogate protection from intravenous SIV challenge in female macaques immunized with an attenuated AIDS virus.

Authors:  Meritxell Genescà; Michael B McChesney; Christopher J Miller
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

Review 9.  Use of nonhuman primate models to develop mucosal AIDS vaccines.

Authors:  Meritxell Genescà; Christopher J Miller
Journal:  Curr HIV/AIDS Rep       Date:  2010-02       Impact factor: 5.071

10.  Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.

Authors:  Caijun Sun; Zhiwei Chen; Xian Tang; Yinfeng Zhang; Liqiang Feng; Yanhua Du; Lijun Xiao; Li Liu; Weijun Zhu; Ling Chen; Linqi Zhang
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.